Loading...

ARCT ARCTURUS THERAPEUTICS HOLDINGS INC Expansion Plans 8-K Filing

RCTR

RCT

ARCTURUS THERAPEUTICS HOLDINGS INC

(ARCT)

2025 8-K

Financial Results Update

Interim Results Report

COVID-19 Vaccine Update

Vaccine Approval Update

Product Expansion

Financial Statements

Financial Results

Financial Results

Corporate Presentation

Financial Results and Corpo...

Appointment of Dr. Moncef S...

Annual Meeting of Stockholders

Earnings Report

Dismissal of Previous Indep...

COVID-19 Vaccine Success

Financial Update

Financial Results and Corpo...

Financial Results and Corpo...

Amendment Agreement with Cy...

Amendment to Collaboration ...

Financial Results and Corpo...

Annual Meeting of Stockholders

Financial Results and Corpo...

COVID-19 Vaccine Submission...

Credit Agreement with Wells...

Distribution Agreement

Financial Results and Corpo...

Termination of Loan Agreement

External Links:

On June 30, 2025, Arcturus Therapeutics Holdings Inc. announced positive interim results for their Phase 2 trial of ARCT-810, an mRNA therapy for treating OTC deficiency, which restores urea cycle activity and prevents health crises.

AI Assistant

ARCTURUS THERAPEUTICS HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.